The data showed beneficial effects of phosphomimetic RLC on the myosin contractile and energetic states in the RCM and DCM myocardium and comparable to treatment with Omecamtiv Mecarbil (OM), a myosin activator developed to increase heart contractility in acute HF and treat systolic dysfunction [29,30]. This evidence concerns the gene MYH14 and hydrops fetalis.